Study to Evaluate a Single Dose of LTX-109 in Subjects With COVID-19 (Coronavirus Disease 2019) Infection.
Status:
Recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
A Phase IIa, double-blind, placebo-controlled, randomised study designed to evaluate the
effect, safety and tolerability of LTX-109 administered topically to the anterior nares in
subjects with COVID-19 infection.
Phase:
Phase 2
Details
Lead Sponsor:
Pharma Holdings AS
Collaborators:
Clinical Trial Consultants AB CTC Clinical Trial Consultants AB